ICON Baird Healthcare Conference Mr. Ciaran Murray – CFO Mr. Brendan Brennan – VP Investor Relations September 10th 2009

Forward Looking Statements Certain statements contained herein including, without limitation, statements containing the words “believes,” “anticipates,” “intends,” “expects” and words of similar import, constitute forward-looking statements concerning the Company's operations, performance, financial condition and prospects. Because such statements involve known and unknown risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors are cautioned not to place undue reliance on such forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This presentation includes selected non-GAAP financial measures. For a presentation of the most directly comparable GAAP financial measures, please refer to the Quarter 2 2009 press release consolidated income statement headed Consolidated Income Statements (Unaudited) (US GAAP)

Global Full Service Clinical Development

ICONs Global Footprint

ICON Plc Staff Growth 1990 - Today

Market Environment

Market Fundamentals Still Intact Outsourcing Penetration expected to increase More Strategic approach to outsourcing Cost containment Globalisation of clinical research Continued R&D Spending Growth. Pipelines remain solid Scientific innovation continues to expand Increasing Regulation More patients/ more studies Post marketing surveillance

Increased Outsourcing Clients are increasingly focused on their core competencies of Discovery Strategic Development Marketing Clients are engaging CROs at a more strategic level Level of management engagement (Executive to executive) Level of co-operative engagement i.e. sharing drug pipeline intentions Deeper reliance on CRO scientific and therapeutic expertise Reduced internal capacity in the companies of strategic partners e.g. staff or asset transfers/reductions Clients likely to move their % outsourced from ≈ 30% to >50% over the next 5+ years

Market Fundamentals Still Intact Outsourcing Penetration expected to increase More Strategic approach to outsourcing Cost containment Globalisation of clinical research Continued R&D Spending Growth. Pipelines remain solid Scientific innovation continues to expand Increasing Regulation More patients/ more studies Post marketing surveillance

Clinical Compounds in Development

R&D Spending Growth

CRO Market Size 1996 – 2012 (E)

Total Biotech Funding ($ Millions)

Market Fundamentals Still Intact Outsourcing Penetration expected to increase More Strategic approach to outsourcing Cost containment Globalisation of clinical research Continued R&D Spending Growth. Pipelines remain solid Scientific innovation continues to expand Increasing Regulation More patients/ more studies Post marketing surveillance

ICON in this Market Environment Opportunities…. but also Risks ICON in this Market Environment

Net Volume of RFPs 2003 to Q2 2009 Net volume represents only those opportunities which were ultimately outsourced

Net New Business Wins and Book to Bill Ratio Net Business Wins

Analysis of Business Wins Q2 09 Net Wins H1 09 Net Wins

Analysis of Backlog by client Q2 09

Total Backlog Level ($ Millions) 14%

Coverage of next 4 quarters from Backlog Value of backlog forecast to be earned in next 4 quarters % coverage of next 4 quarters forecast revenues

Projects of Longer duration lead to slower backlog burn

Strategy

ICON’s Core Strategy is Organic Growth, with acquisitions made to add new services or scale Capitalise on market fundamentals to drive organic growth in all business units. Cross-sell services to grow sales and margin Build Deep Strategic Relationships Create Stronger differentiation across our services Retain a flexible business model to respond to differing client outsourcing strategies Pursue acquisitions to enhance depth and scale of current operations and to add additional complementary services e.g. Safety/Late Phase Imaging Japan Acquisitions to date – 13 Revenues acquired $130m Staff acquired – 1,200 => Organic growth >80% Phase I Bioanalytical / Biomarkers Therapeutic specialists

Market Feedback

ICON in recent Surveys “ICON is one of three CRO’s cited most frequently as sponsor’s favourite CRO vendors” “Our confidence goes up that ICON is the right name to own in this environment, given their consistent quality” ““ ICON is a darling of the industry, the company's stunning growth in 2006 and 2007 surprised its peers. Now, the Dublin-based company is still outpacing just about everybody, but at a less accelerated clip.”

Financial Performance

Net Revenue CAGR of 28% since 2005 * Mid point of Guidance July 22nd

Earnings Per Share Growth CAGR 35% * Mid point of Guidance July 22nd

Cash Flow from Operations / Free Cash Flow FCF Per Share * Estimate assumes DSO of approx 60 days. Historic periods FCF exclude Head-office construction costs

Return on Equity

Recent Financial Performance ($ millions) Quarter 2 2009 30 June 09 30 June 08 % Increase Net Revenue 220 218 1% Direct Costs 125 123 1.8% SG & A EBITDA 58 37 64 31 (7.1%) 19% D & A 8 7 13% EBIT 29 24 20% Net Income 23 19 21% EPS (Inc SFAS 123R) 38c 31c 23% Weighted Average no. of Shares (Inc SFAS123R) 59.7m 60.3m (1.1%)

Recent Financial Performance ($ millions) H1 2009 30 June 09 30 June 08 % Increase Net Revenue 440 420 5% Direct Costs 249 236 6% SG & A EBITDA 119 71 125 59 21% D & A 15 13 18% EBIT 56 46 23% Net Income 44 36 22% EPS (Inc SFAS 123R) 73c 59c 24% Weighted Average no. of Shares (Inc SFAS123R) 59.7m 60.2m (0.7%)

Summary Balance Sheet and Cash Flow ($ millions) H1 ended Jun 30, 09 Full Year ended Dec 31, 08 Dec 31, 07 Dec 31, 06 Cash $147.3 $101.1 $118.6 $102.9 Debt $64.1 $105.4 $94.8 $5 Net Cash/Debt $83.2 ($4.3) $23.8 $97.9 Total assets $897.5 $867.3 $693.1 $476.3 Total Liabilities $389.5 $410.9 $304.9 $173.6 Shareholder’s equity $507.9 $456.4 $388.4 $302.7 Cashflow from operations $128 $81.3 $42.9 $50.4 Capital expenditures $16.4 $67.9 $75.4 $31.5

ICON Key Financial Metrics ($ millions) Qtr ended Jun 30, 09 Full Year ended Dec 31, 08 Dec 31, 07 Dec 31, 06 Sales Growth 5% 37% 38% 39% EPS Growth 24% 41% 177% EBITDA Margin 16.2% 14.7% 14% 13.8% EBIT Margin 12.8% 11.5% 11.0% 10.5% ROE 17.7% 17% 13%

ICON Plc Historic Share Price Performane S&P 500 Nasdaq Composite

Investment Case Summary Top Global Clinical CRO - #4 Deep customer relationships Quality of staff Experienced Management team Excellent Reputation Solid market fundamentals Outstanding record of growth Strong balance sheet